Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ke Shu

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Blood Advances|February 24, 2026
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adultsYan Xie, Ke-Shu Zhou, Lan-Fang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Blood Advances|April 20, 2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLi-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, et al.
Cancer Communications (London, England)|May 9, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT studySi-Yuan Chen, Peng-Peng Xu, Ru Feng, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Blood Advances|February 24, 2026
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adultsYan Xie, Ke-Shu Zhou, Lan-Fang Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
Blood Advances|April 20, 2023
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLi-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, et al.
Cancer Communications (London, England)|May 9, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT studySi-Yuan Chen, Peng-Peng Xu, Ru Feng, et al.
Pageof 7